Table 2

Percentage and absolute counts of circulating immune cells for the three patients

Patient 1Reference values*Patient 2Reference values*Patient 3 Reference values†
Age (years)16 (10–16) 8 (5–10) 7.58 (5–10)
TreatmentNoEtanercept and isotretinoin orallyAnakinra
White cell count (/109/L)1310.516.3
Neutrophils (%)
(/mm3)		72
9360
(1700–5700) 		54
5670
(1500–5900)
Lymphocytes (%)
(/mm3)		17
2250		 35.3
(1400–4200) 		11
1103
(1200–4700) 		4.85
791
(1100–5900)
T lymphocytes CD3+ (%)
(/mm3)		77
1732
(850–3200) 		78
860
(770–4000) 		3725
200
(700–4200)
T lymphocytes CD4+ (%)
(/mm3)		35
788		51
562		30
500
 Regulatory
CD4+CD127lowCD25high 		(%)
(/mm3)		7
55		7
39
 Naive
CD4+CD45RA+ 		(%)
(/mm3)		32
252		62
349		95
475
 Memory
CD4+CD45 RO+ 		(%)
(/mm3)		67
528		38
214		60
300
T lymphocytes CD8+ (%)34225
Activated T lymphocytes
CD3+HLA-DR+ (%)		112
B lymphocytes CD19+ (%)
(/mm3)		20
450
(120–740) 		17
187
(100–800) 		30
500		69
550
(200–1600)
 Transitional
CD24highCD38high 		(%)
(/mm3)		18
81		 5 (1–25)
(3–88) 		19
36		 8 (2–30)
8–73 		22
122
(11–77)
 Naive
IgD+CD27− 		(%)
(/mm3)		84
378		 74 (49–100)
(60–700) 		76
142		 76 (62–94)
(70–630) 		64.1
353
(111–486)
 MZ natural effector
IgD+CD27+ 		(%)
(/mm3)		5
23		 (2–28)
(9–57) 		3
6 		(4–24)
(8–86) 		2.4
13
(15–88)
 Memory
IgD−CD27+ 		(%)
(/mm3)		9
41
(7–73) 		17
32
(7–51) 		3

2
13
(13–100)
NKCD56+CD3−(%)
(/mm3)		6
135
(92–1200) 		3
33
(70–590) 		34
600		32
260
(90–900)

  • Out-of-range numbers are in bold. Reference values are in italic.

  • *Age-matched reference (mean (range)) values from Schatorjé et al.17

  • †Age-matched reference (mean (range)) values from University Medicals Center St Radboud, Nijmegen, the Netherlands.

  • MZ, marginal zone; HLA-DR, human leucocyte antigen -antigen D related.